

**REMARKS**

Claims 1-8 and 11-15 are currently pending in the application. With this Amendment, claims 3 and 12-15 are amended to correct minor typographical errors. No new matter is added.

The Restriction Requirement of the Office Action mailed on May 30, 2002, required restriction to one of the following invention groups as stated in the Office Action:

Group I: Claims 1-4, 8, 11-13 and 15 drawn to pharmaceutical compositions and method for treating cancerous diseases employing the compound of formula I alone. Which is class 514, subclass 492.

Group II: Claims 5-7 and 14 drawn to pharmaceutical compositions of the compound of formula I and another active agent such as interferon, which is in class 424, subclass 85.4.

Applicants acknowledge a telephone interview with Examiner Jerome D. Goldberg on June 24, 2002, in which the Restriction Requirement was discussed, in particular that claim 7 should more correctly appear in Group I as claim 7 recites a pharmaceutical preparation provided in a unit dosage form and does not specify the presence of an additional active agent. Thus, Applicants and Examiner agreed that claim 7 should be included in Group I.

In response to the Restriction Requirement of the Office Action mailed on May 30, 2002, Applicants elect **Group I, Claims 1-4, 7, 8, 11-13 and 15** (including claim 7) for prosecution on the merits, with traverse.


This Response is being filed within 30 days from the Restriction Requirement mailed on May 30, 2002 and no fee is believed to be due. However, should any fees be required to ensure consideration of this response, the Commissioner is authorized to charge Deposit Account 16-0085, Reference No. 8654/2002.

**CONCLUSION**

Applicants submit that pending claims 1-8 and 11-15 are allowable as written and respectfully request early favorable action by the Examiner. If the Examiner believes that a telephone conversation with Applicants' attorney would expedite prosecution of this application, the Examiner is cordially invited to call the undersigned attorney of record.

Date: June 26, 2002

Respectfully submitted,



Name: David J. Dykeman

Registration No.: 46,678

Customer No.: 29933


Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Telephone: (617) 239-0100

Telecopier: (617) 227-4420

MARKED-UP VERSION OF AMENDMENTS:

RECEIVED

JUL 0 5 2002

Claim Amendments Under 37 C.F.R. § 1.121(c)(1)(ii)COPY OF PAPERS  
ORIGINALLY FILED

TECH CENTER 1600/2900

Please amend claims 3 and 12-15 as follows:

3. (Amended) The pharmaceutical preparation according to claim 1, wherein in the compound of formula (I) [wherein] R<sub>1</sub> and R<sub>2</sub> are CH<sub>3</sub>CH<sub>2</sub> each.
12. (Amended) A method of treating [cancer] cancerous disease, comprising administering the preparation of claim 1 in an amount effective to treat said [cancer] cancerous disease.
13. (Amended) The method of claim 12, wherein said [cancer] cancerous disease is parvocellular bronchial carcinoma or colorectal carcinoma.
14. (Amended) The pharmaceutical preparation according to claim 6, wherein the further cytostatic agent is cisplatin, methotrexate, aminopterin, [dcarbazine] dacarbazine, nitroso urea compounds, fluorouracil, bleomycin, daunomycin, daunorubicin, doxorubicin, mithramycin, or mitomycin C.
15. (Amended) The [use] method according to claim [10] 12, wherein said cancerous disease is selected from testicular tumors, ovarian carcinomas, bladder carcinomas, colonic carcinomas, prostatic carcinomas, parvocellular and non-parvocellular bronchial carcinomas, carcinomas of the cephalic and cervical parts, carcinomas of the thoracic and abdominal regions, [cervical] cervical and endometrial carcinomas, sarcomas, melanomas and leukemias.